Stocks Health care ALVO
NASDAQ · Health careAlvotech (ALVO)
Alvotech reported revenue of $586.3M in fiscal 2025, up 19.7% from a year earlier. Net income was $27.9M, a net margin of 4.8%. In fiscal 2025 capital spending exceeded operating cash flow by $114.7M. At December 31, 2025 it held $172.4M in cash against $1.3B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.
What Alvotech does
Alvotech is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALVO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $586.3M | $27.9M | $0.10 | -$114.7M |
| 2024 | $489.7M | -$231.9M | -$0.87 | -$290.5M |
| 2023 | $91.4M | -$551.7M | -$2.43 | -$345.4M |
| 2022 | $83M | -$513.6M | -$2.60 | -$350.3M |
| 2022 | $36.8M | -$101.5M | -$0.92 | -$248.6M |
| 2020 | $66.6M | -$170M | -$1.82 | -$81.8M |
Latest SEC filings
What Alvotech has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 31, 2026
- August 21, 2026
- August 19, 2026
- July 29, 2026
- July 1, 2026
- June 30, 2026Activist stake changed SCHEDULE 13D/A
- June 18, 2026
- June 17, 2026
- June 16, 2026
- June 16, 2026
Questions about ALVO
What does Alvotech do?
Alvotech is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALVO.
Is Alvotech profitable?
Yes. In fiscal 2025 it reported net income of $27.9M on revenue of $586.3M, a net margin of 4.8%.
How much revenue does Alvotech make?
In fiscal 2025 Alvotech reported revenue of $586.3M. That is 19.7% more than a year earlier.
When did Alvotech last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 31, 2026.
Similar companies
Follow ALVO
Get an email when Alvotech files with the SEC: results, executive changes, material agreements and annual reports.
Follow ALVO: get an email when it filesWhere the numbers come from
Financial figures are the values Alvotech tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.